Terms: = Endocrine gland cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Diagnosis
17 results:
1. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
De Simoni O; Dal Santo L; Scarpa M; Munari G; Spolverato YC; Scapinello A; Lonardi S; Soldà C; Bergamo F; Fantin A; Bardini R; Pilati P; Fassan M; Gruppo M
Curr Oncol; 2023 Jun; 30(6):5515-5528. PubMed ID: 37366900
[TBL] [Abstract] [Full Text] [Related]
2. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
[TBL] [Abstract] [Full Text] [Related]
3. Effect of FOXP2 transcription factor on immune infiltration of thyroid cancer and its potential clinical value.
Xu L; Yang Z; Zhao Q; Feng H; Kuang J; Liu Z; Chen L; Zhan L; Yan J; Cai W; Qiu W
Front Immunol; 2022; 13():982812. PubMed ID: 36203616
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.
Marchenko S; Piwonski I; Hoffmann I; Sinn BV; Kunze CA; Monjé N; Pohl J; Kulbe H; Schmitt WD; Darb-Esfahani S; Braicu EI; von Brünneck AC; Sehouli J; Denkert C; Horst D; Jöhrens K; Taube ET
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2523-2536. PubMed ID: 35763108
[TBL] [Abstract] [Full Text] [Related]
5. The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC).
Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Zvirblis T; Sileikis A
Anticancer Res; 2022 Jun; 42(6):3067-3073. PubMed ID: 35641268
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract] [Full Text] [Related]
7. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract] [Full Text] [Related]
8. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
Fan K; Yang C; Fan Z; Huang Q; Zhang Y; Cheng H; Jin K; Lu Y; Wang Z; Luo G; Yu X; Liu C
Cancer Lett; 2018 Apr; 418():167-175. PubMed ID: 29337110
[TBL] [Abstract] [Full Text] [Related]
9. Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of foxp3+ T lymphocytes.
Pilli T; Toti P; Occhini R; Castagna MG; Cantara S; Caselli M; Cardinale S; Barbagli L; Pacini F
J Endocrinol Invest; 2018 Jun; 41(6):703-709. PubMed ID: 29230715
[TBL] [Abstract] [Full Text] [Related]
10. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian cancer: A Brief Report.
Cannioto RA; Sucheston-Campbell LE; Hampras S; Goode EL; Knutson K; Ness R; Modugno F; Wallace P; Szender JB; Mayor P; Hong CC; Joseph JM; Friel G; Davis W; Nesline M; Eng KH; Edwards RP; Kruszka B; Schmitt K; Odunsi K; Moysich KB
Int J Gynecol Cancer; 2017 Jan; 27(1):11-16. PubMed ID: 27759594
[TBL] [Abstract] [Full Text] [Related]
11. CD25 identifies a subset of CD4⁺foxp3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract] [Full Text] [Related]
12. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.
Cunha LL; Marcello MA; Morari EC; Nonogaki S; Conte FF; Gerhard R; Soares FA; Vassallo J; Ward LS
Endocr Relat Cancer; 2013 Feb; 20(1):103-10. PubMed ID: 23193072
[TBL] [Abstract] [Full Text] [Related]
13. The similarity of Type 1 autoimmune pancreatitis to pancreatic ductal adenocarcinoma with significant IgG4-positive plasma cell infiltration.
Fukui Y; Uchida K; Sumimoto K; Kusuda T; Miyoshi H; Koyabu M; Ikeura T; Sakaguchi Y; Shimatani M; Fukui T; Matsushita M; Takaoka M; Nishio A; Shikata N; Sakaida N; Uemura Y; Satoi S; Kwon AH; Okazaki K
J Gastroenterol; 2013 Jun; 48(6):751-61. PubMed ID: 23053421
[TBL] [Abstract] [Full Text] [Related]
14. foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas.
Cunha LL; Morari EC; Nonogaki S; Soares FA; Vassallo J; Ward LS
Clinics (Sao Paulo); 2012; 67(5):483-8. PubMed ID: 22666793
[TBL] [Abstract] [Full Text] [Related]
15. Usefulness of endoscopic biopsy using foxp3+ Treg up-regulation in the duodenal papilla in the differential diagnosis between autoimmune pancreatitis and pancreatic cancer.
Kubota K; Kato S; Watanabe S; Fujita K; Yoneda M; Takahashi H; Inamori M; Shimamura T; Kirikoshi H; Kobayashi N; Saito S; Hisatomi K; Matsuhashi N; Nakajima A
J Hepatobiliary Pancreat Sci; 2011 May; 18(3):414-21. PubMed ID: 21113630
[TBL] [Abstract] [Full Text] [Related]
16. Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Bussom S; Saif MW
JOP; 2010 Mar; 11(2):131-4. PubMed ID: 20208320
[TBL] [Abstract] [Full Text] [Related]
17. The impact of T-cell immunity on ovarian cancer outcomes.
Nelson BH
Immunol Rev; 2008 Apr; 222():101-16. PubMed ID: 18363996
[TBL] [Abstract] [Full Text] [Related]
